NuvOx Pharma, LLC

NuvOx Pharma LLC is a clinical-stage biopharmaceutical company based in the US, focusing on developing innovative oxygen therapeutics to treat tissue hypoxia in severe medical conditions. Founded in 2008 and headquartered in Tucson, US, NuvOx Pharma LLC specializes in oxygen therapeutics for life-threatening diseases. The company, led by CEO Evan Unger, has raised a total of USD 0. 50 mn from collaborations and grants, with its most recent deal being a Grant of USD 0.

90 mn from the National Institute of Neurological Disorders and Stroke in June 2023. NuvOx Therapeutics is focused on developing innovative oxygen therapeutics designed to address tissue hypoxia, which is critical in various life-threatening diseases. Their flagship product, NanO₂, is currently under clinical investigation for multiple indications, including glioblastoma, stroke, and respiratory distress. The primary function of NanO₂ is to enhance oxygen flow from the lungs to the bloodstream and subsequently to tissues, potentially improving patient outcomes in severe medical conditions.

The company is actively enrolling patients in clinical trials with support from the National Institute of Neurological Disorders and Stroke and the National Institute of Health and Care Research in the UK, targeting healthcare providers and institutions managing critical care, oncology, and neurology patients. NuvOx Therapeutics operates within a clinical-stage framework and has not yet generated commercial revenue from product sales. Their business model relies on partnerships and collaborations with governmental and research institutions to fund their clinical trials and development efforts. Collaborations may include grants from the National Institute of Health and Care Research and the Biomedical Advanced Research and Development Authority, facilitating their clinical research activities.

As NuvOx advances its products through the development pipeline, potential revenue streams may emerge upon successful product approvals, likely involving agreements with healthcare providers and pharmaceutical distributors for the deployment of their therapeutics in clinical settings, focusing on B2B relationships with hospitals and treatment facilities. Looking ahead, NuvOx is focused on advancing its clinical trials for NanO₂, with plans to expand into additional markets in the US and the UK by 2024. The recent Grant of USD 0. 90 mn will support their clinical research and development initiatives, enhancing their capability to address tissue hypoxia in patients.

Furthermore, the company is exploring opportunities to introduce new products aimed at other medical conditions associated with oxygen deficiency.